REDWOOD CITY, Calif., Nov. 09, 2016 -- Dextera Surgical Inc. (Nasdaq:DXTR), manufacturer of the smallest-profile and most maneuverable articulating surgical stapling platform on the market for minimally invasive surgery, today announced that Julian Nikolchev, president and CEO, will present a corporate update at the 7th Annual Craig-Hallum Alpha Select Conference on November 16, 2016 at 1:30 p.m. Eastern Time.
To access the live and subsequently archived webcast of the presentation, go to the Investor Relations section of the company’s website at ir.dexterasurgical.com. Please connect to the website at least 15 minutes prior to the presentation to allow for any necessary software downloads.
About Dextera Surgical
Dextera Surgical (Nasdaq:DXTR) designs and manufactures proprietary stapling devices for minimally invasive surgical procedures. In the U.S., surgical staplers are routinely used in more than one million minimally invasive laparoscopic, video-assisted or robotic-assisted surgical procedures annually.
The company's signature proprietary technology, the MicroCutter 5/80 Stapler, is the world's first and only five-millimeter surgical stapler that articulates to 80 degrees in each direction. As the smallest-profile articulating stapler available today, the MicroCutter 5/80 Stapler may reduce the amount of dissection and tissue handling required to position the stapler in confined spaces, enabling access to difficult-to-reach anatomy. The cartridge-based device's small size and wide articulation range are designed to enhance the surgeon's access and visualization at the surgical site and to mitigate limitations on the advancement of minimally invasive surgical approaches created by larger stapling devices.
Dextera Surgical also markets the only automated anastomosis devices for coronary artery bypass graft (CABG) surgery on the market today: the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System. These products, sold by Dextera Surgical under the Cardica brand name, have demonstrated long-term reliable clinical performance for more than a decade.
Contact: Investors: Bob Newell Vice President, Finance and Chief Financial Officer +1 (650) 331-7133 [email protected] Media: Jessica Volchok +1 (310) 849-7985 [email protected]


Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 



